SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Calais G, Berger C, Descamps P, et al. Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm. Cancer. 1994; 74: 12831288.
  • 2
    Forrest AP, Levack PA, Chetty U, et al. A human tumor model. Lancet. 1986; 2: 840842.
  • 3
    Jacquillat C, Weil M, Baillet F, et al. Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer. 1990; 66: 119129.
  • 4
    Bonadonna G, Veronesi U, Brambilla C, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimetres or more. J Natl Cancer Inst. 1990; 82: 15391545
  • 5
    Bonadonna G, Valagussa P, Brambilla C, et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol. 1998; 16: 93100.
  • 6
    Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999; 17: 460469.
  • 7
    Mamounas EP. Neoadjuvant chemotherapy for operable breast cancer: is this the future? Clin Breast Cancer. 2003; 4(Suppl. 1): S10S19.
  • 8
    Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997; 15: 24832493.
  • 9
    Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998; 16: 26722685.
  • 10
    Mauriac L, Durand M, Avril A, Dilhuydy JM. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. Ann Oncol. 1991; 2: 347354.
  • 11
    Mauriac L, MacGrogan G, Avril A, et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol. 1999; 10: 4752.
  • 12
    Scholl SM, Fourquet A, Asselain B, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumors considered too large for breast conserving surgery: preliminary results of a randomized trial: S6. Eur J Cancer. 1994; 30A: 645652.
  • 13
    Powles TJ, Hickish TF, Makris A, et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol. 1995; 13: 547552.
  • 14
    Miller KD, McCaskill-Stevens W, Sisk J, et al. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: a randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol. 1999; 17: 30333037.
  • 15
    Bellino R, Cortese P, Danese S, et al. Epidoxorubicin and paclitaxel as primary chemotherapy for T > 3 cm and T4 breast cancer patients. Anticancer Res. 2000; 20: 48254828.
  • 16
    de Matteis A, Nuzzo F, D'Aiuto G, et al. Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: a single-center, phase II study. Cancer. 2002; 94: 895901.
  • 17
    Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer. Significantly enhanced response with docetaxel. J Clin Oncol. 2002; 20: 14561466.
  • 18
    Ganem G, Tubiana-Hulin M, Fumoleau P, et al. Phase II trial combining docetaxel and doxorrubicin as neoadjuvant chemotherapy in patients with operable breast cancer. Ann Oncol. 2003; 14: 16231628.
  • 19
    Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003; 21: 41654174.
  • 20
    Heys SD, Hutcheon AW, Sarkar TK, et al. Aberdeen Breast Group. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer. 2002; 3(Suppl. 2): S69S74.
  • 21
    Moreno A, Escobedo A, Benito E, Serra JM, Guma A, Riu F. Pathologic changes related to CMF primary chemotherapy in breast cancer. Pathological evaluation of response predicts clinical outcome. Breast Cancer Res Treat. 2002; 75: 119125.
  • 22
    Fisher B, Redmond C, Fisher ER, et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med. 1985; 312: 674681.
  • 23
    Veronesi U, Banfi A, Salvadori B, et al. Breast conservation is the treatment of choice in small breast cancer: long-term results of a randomized trial. Eur J Cancer. 1990; 26: 668670.
  • 24
    Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol. 2003; 21: 33573365. Epub 2003 Jul 07. Review.
  • 25
    Skipper HE. Kinetics of mammary tumor cell growth and implications for therapy. Cancer. 1971; 28: 14791499.
  • 26
    Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet. 1998; 351: 14511467.
  • 27
    Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003; 21: 976983.